Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Richard_Pops
|
| gptkbp:countryOfOrigin |
gptkb:Ireland
|
| gptkbp:developedBy |
medications for addiction
medications for bipolar disorder medications for cancer medications for depression medications for schizophrenia |
| gptkbp:focusesOn |
oncology
central nervous system disorders |
| gptkbp:founded |
1987
|
| gptkbp:founder |
gptkb:Michael_Wall
|
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alkermes
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
IE00B56GVS15
|
| gptkbp:numberOfEmployees |
~2,200 (2023)
|
| gptkbp:product |
gptkb:Aristada
gptkb:Lybalvi gptkb:Vivitrol |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_ALKS
|
| gptkbp:USOperations |
gptkb:Waltham,_Massachusetts,_USA
|
| gptkbp:website |
https://www.alkermes.com/
|
| gptkbp:bfsParent |
gptkb:Sofinnova_Investments
|
| gptkbp:bfsLayer |
6
|